Novartis, developer of the brand-name Lucentis, announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted the drug a positive opinion for the treatment of retinopathy of prematurity in infants.
Biosimilars of ranibizumab (Lucentis) are on the horizon, with developers including Xbrane, Coherus BioSciences, and Samsung Bioepis all advancing proposed biosimilars referencing the anti—vascular endothelial growth factor (anti-VEGF) therapy. However, ahead of facing competition, the eye drug could gain a new European indication.
Novartis, developer of the brand-name Lucentis, announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted the drug a positive opinion for the treatment of retinopathy of prematurity (ROP) in infants. ROP is a rare eye disease that is the leading cause of childhood blindness. ROP affects premature infants and is caused by the abnormal development of retinal blood vessels spurred by high levels of VEGF.
If ranibizumab is approved in this indication, it will be the first time that a drug has been approved for this patient population.
The CHMP opinion relied on data from the RAINBOW clinical study, which was conducted among 224 participants at 87 sites worldwide. Patients with ROP were randomized to receive 1 of 3 therapies: 0.2 mg of ranibizumab injected on day 1 and up to 2 retreatments for each eye, 0.1 mg of ranibizumab on day 1 and up to 2 retreatments per eye, or laser therapy.
The primary outcome measure was the percentage of patients with an absence of active ROP and an absence of unfavorable structural outcomes in both eyes at week 24. In total, 80% of patients who received 0.2 mg of ranibizumab and 75% of those who received 0.1 mg of ranibizumab achieved this outcome versus 66.2% of patients who received laser therapy. Adverse events were reported in 35.62%, 31.58%, and 34.78% of patients in the 3 groups, respectively.
“Given this vulnerable patient population, and the limitations of current treatments, randomized controlled clinical studies are important to ensure safe and effective use of pharmacological therapies in pediatric patient populations. If approved, ranibizumab will be a valuable alternative treatment option to laser therapy,” commented Andreas Stahl, MD, director of the department of ophthalmology, University Medical Center Greifswald, in a statement announcing the CHMP opinion.
Novartis indicated that it expects to receive the European Commission’s decision on the drug within the next 3 months.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.